AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34467621 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary diversification and nutrition education strategies
Number of subjects: 390
Study 33385533 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin Infiltration (Icon)
Number of subjects: 51
Study 33385533 — intervention group
Group type: COMPARATOR
Intervention: Fluoride Varnish (Duraphat)
Number of subjects: 51
Study 33385533 — intervention group
Group type: COMPARATOR
Intervention: Fluoride Varnish (Duraphat) after enamel etching with 37% phosphoric acid
Number of subjects: 51
Study 36454345 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Shot Dilatation (Group A)
Number of subjects: 129
Study 36454345 — intervention group
Group type: COMPARATOR
Intervention: Serial Dilatation (Group B)
Number of subjects: 129
Study 33501942 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor fecal microbiota transplantation
Number of subjects: 26
Study 33501942 — intervention group
Group type: COMPARATOR
Intervention: Placebo (autologous transplant)
Number of subjects: 26
Study 33501942 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor fecal microbiota transplantation (subgroup analysis)
Number of subjects: 26
Study 33501942 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subgroup analysis)
Number of subjects: 26
Study 35148378 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Number of subjects: 34
Study 35148378 — intervention group
Group type: COMPARATOR
Intervention: Best available therapy
Number of subjects: 34
Study 35148378 — intervention group
Group type: COMPARATOR
Intervention: High-dose meropenem
Number of subjects: 34
Study 33685512 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention
Number of subjects: 165397
Study 33685512 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 165397
Study 32020356 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (EX, n=19)
Number of subjects: 37
Study 32020356 — intervention group
Group type: COMPARATOR
Intervention: Health education intervention (HE, n=18)
Number of subjects: 37
Study 36151535 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision Family Spirit (PFS)
Number of subjects: 60
Study 36151535 — intervention group
Group type: COMPARATOR
Intervention: Standard Family Spirit (Standard FS)
Number of subjects: 60
Study 36151535 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PFS and Standard FS)
Number of subjects: 60
Study 32358349 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with conventional therapy
Number of subjects: 66
Study 32358349 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 66
Study 34989759 — intervention group
Group type: EXPERIMENTAL
Intervention: Flower essence therapy (4 drops, 4 times a day for 60 days)
Number of subjects: 101
Study 34989759 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 drops, 4 times a day for 60 days)
Number of subjects: 101
Study 35029097 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital workflow group (prefabricated prostheses with anchor pin attachment system)
Number of subjects: 6
Study 35029097 — intervention group
Group type: COMPARATOR
Intervention: Conventional workflow group (conventional procedure for provisional prosthesis)
Number of subjects: 6
Study 34849651 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard ATT plus daily 1000 mg metformin (METRIF)
Number of subjects: 322
Study 34849651 — intervention group
Group type: COMPARATOR
Intervention: Standard ATT (HREZ)
Number of subjects: 322
Study 32979939 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose varenicline (1 mg twice daily; 0.5 mg twice daily if bodyweight ≤55 kg)
Number of subjects: 312
Study 32979939 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose varenicline (0.5 mg twice daily; 0.5 mg once daily if bodyweight ≤55 kg)
Number of subjects: 312
Study 32979939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study 35017115 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of anal HSIL
Number of subjects: 0
Study 35017115 — intervention group
Group type: COMPARATOR
Intervention: Active monitoring
Number of subjects: 0
Study 32763541 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline plus enhanced medication management (EMM)
Number of subjects: 0
Study 32763541 — intervention group
Group type: COMPARATOR
Intervention: PE plus placebo
Number of subjects: 0
Study 32763541 — intervention group
Group type: EXPERIMENTAL
Intervention: PE plus sertraline hydrochloride
Number of subjects: 0
Study 32763541 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 0
Study 34190422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) at doses of 600 or 1000 mg per day for 12 weeks
Number of subjects: 405
Study 34190422 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 405
Study 34780511 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening Restriction intervention (no screen media use after six pm)
Number of subjects: 12
Study 34780511 — intervention group
Group type: EXPERIMENTAL
Intervention: General Restrict intervention (limit entertainment-based screen media to three hours/week/person)
Number of subjects: 12
Study 34780511 — intervention group
Group type: EXPERIMENTAL
Intervention: General Restrict intervention
Number of subjects: 12
Study 34780511 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometry wear protocol
Number of subjects: 12
Study 34780511 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategy
Number of subjects: 12
Study 33749975 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone acetonide (TrA)
Number of subjects: 40
Study 33749975 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional methotrexate (MTX)
Number of subjects: 40
Study 33749975 — intervention group
Group type: COMPARATOR
Intervention: Both groups (TrA and MTX)
Number of subjects: 40
Study 34382289 — intervention group
Group type: EXPERIMENTAL
Intervention: Musculoskeletal pain
Number of subjects: 486
Study 34382289 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache
Number of subjects: 486
Study 34382289 — intervention group
Group type: EXPERIMENTAL
Intervention: Fever
Number of subjects: 486
Study 34382289 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal pain
Number of subjects: 486
Study 34065454 — intervention group
Group type: EXPERIMENTAL
Intervention: Wu-style Tai Chi (60 min, 3 times a week for 6 weeks)
Number of subjects: 66
Study 34065454 — intervention group
Group type: COMPARATOR
Intervention: Simplified Tai Chi (3 times a week for 6 weeks)
Number of subjects: 66
Study 34065454 — intervention group
Group type: EXPERIMENTAL
Intervention: Wu-style Tai Chi
Number of subjects: 66
Study 34516033 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D replacement (n=21)
Number of subjects: 59
Study 34516033 — intervention group
Group type: EXPERIMENTAL
Intervention: Core and balance exercises (n=18)
Number of subjects: 59
Study 34516033 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D replacement plus core and balance exercises (n=20)
Number of subjects: 59
Study 34516033 — intervention group
Group type: COMPARATOR
Intervention: Core and balance exercises (n=40) - Control group
Number of subjects: 59
Study 34964262 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin during pregnancy
Number of subjects: 73
Study 34964262 — intervention group
Group type: EXPERIMENTAL
Intervention: Post partum metformin concentration
Number of subjects: 73
Study 34060169 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy education (four weekly training sessions)
Number of subjects: 206
Study 34060169 — intervention group
Group type: COMPARATOR
Intervention: Control group (no health literacy education)
Number of subjects: 206
Study 32233704 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate
Number of subjects: 1338
Study 32233704 — intervention group
Group type: COMPARATOR
Intervention: pH
Number of subjects: 1338
Study 36477274 — intervention group
Group type: EXPERIMENTAL
Intervention: Allis clamp
Number of subjects: 95
Study 36477274 — intervention group
Group type: COMPARATOR
Intervention: Single-tooth tenaculum
Number of subjects: 95
Study 36477274 — intervention group
Group type: EXPERIMENTAL
Intervention: Allis clamp and Single-tooth tenaculum
Number of subjects: 95
Study 33141277 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic surgery (SPLS)
Number of subjects: 359
Study 33141277 — intervention group
Group type: COMPARATOR
Intervention: Multiport laparoscopic surgery (MPLS)
Number of subjects: 359
Study 32380679 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic balance exercises with visual feedback (VF)
Number of subjects: 30
Study 32380679 — intervention group
Group type: COMPARATOR
Intervention: Dynamic balance exercises without visual feedback (control)
Number of subjects: 30
Study 34508365 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment reminders (outpatient appointment reminders a day before appointment and medication reminders on a weekly basis)
Number of subjects: 183
Study 34508365 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without reminders
Number of subjects: 183
Study 33929052 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity shockwave therapy (LiST) applied once weekly for 6 weeks
Number of subjects: 50
Study 33929052 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity shockwave therapy (LiST) applied twice weekly for 3 weeks
Number of subjects: 50
Study 33929052 — intervention group
Group type: COMPARATOR
Intervention: Comparison between once weekly and twice weekly LiST
Number of subjects: 50
Study 35300814 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelacarsen (20-80 mg cumulative monthly doses)
Number of subjects: 0
Study 35300814 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelacarsen
Number of subjects: 0
Study 34066319 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-session multicomponent intervention program based on group psychological therapy and adventure activities
Number of subjects: 34
Study 34066319 — intervention group
Group type: COMPARATOR
Intervention: Control group (details of control not specified)
Number of subjects: 34
Study 34863926 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP)
Number of subjects: 15
Study 34863926 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 15
Study 34863926 — intervention group
Group type: COMPARATOR
Intervention: Both MP and CBT
Number of subjects: 15
Study 34689452 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,000 ppm sodium fluoride (F5000)
Number of subjects: 150
Study 34689452 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,450 ppm sodium fluoride (F1450)
Number of subjects: 150
Study 34689452 — intervention group
Group type: COMPARATOR
Intervention: Control (deionized water)
Number of subjects: 150
Study 32380852 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month home-based exercise program with four physiotherapy follow-up visits
Number of subjects: 45
Study 32380852 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative exercise instructions
Number of subjects: 45
Study 35175414 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous scopolamine before stapling
Number of subjects: 100
Study 35175414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 33125080 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH
Number of subjects: 61
Study 33125080 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 61
Study 33852380 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive military exoskeleton
Number of subjects: 0
Study 33852380 — intervention group
Group type: COMPARATOR
Intervention: Mass-matched control condition
Number of subjects: 0
Study 34569421 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical closure of the vaginal cuff
Number of subjects: 0
Study 34569421 — intervention group
Group type: COMPARATOR
Intervention: Horizontal closure of the vaginal cuff
Number of subjects: 0
Study 34569421 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques (Vertical and Horizontal closure)
Number of subjects: 0
Study 35230177 — intervention group
Group type: EXPERIMENTAL
Intervention: PartyWise intervention (telephone screening, brief counseling, web-based resources, and up to 8 weekly text messages)
Number of subjects: 520
Study 35230177 — intervention group
Group type: EXPERIMENTAL
Intervention: PartyWise intervention
Number of subjects: 520
Study 35230177 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 520
Study 33549112 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding duration > 6 months
Number of subjects: 10464
Study 33549112 — intervention group
Group type: COMPARATOR
Intervention: Neonatal and familial risk factors
Number of subjects: 10464
Study 35705264 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral posterior quadratus lumborum block (QLB) with 20 mL of 0.375% ropivacaine on each side (150 mg total)
Number of subjects: 56
Study 35705264 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal morphine (0.4 mg morphine sulfate)
Number of subjects: 56
Study 35705264 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral posterior quadratus lumborum block (QLB)
Number of subjects: 56
Study 33300420 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow restriction (BFR) training
Number of subjects: 18
Study 33300420 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity strength training without BFR (Control)
Number of subjects: 18
Study 35337143 — intervention group
Group type: EXPERIMENTAL
Intervention: Chisan®/ADAPT‐232 (a fixed combination of adaptogens Rhodiola, Eleutherococcus, and Schisandra) supplementation for two weeks
Number of subjects: 100
Study 35337143 — intervention group
Group type: EXPERIMENTAL
Intervention: Chisan® treatment
Number of subjects: 100
Study 35337143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 33411684 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-directional Mendelian randomization (MR) analysis
Number of subjects: 0
Study 33411684 — intervention group
Group type: EXPERIMENTAL
Intervention: cFDR method
Number of subjects: 0
Study 35181380 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Nutri- and Eco-Score at product level
Number of subjects: 1000
Study 35181380 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation agents
Number of subjects: 1000
Study 35181380 — intervention group
Group type: EXPERIMENTAL
Intervention: Display of average impact scores of the selected basket and social norms
Number of subjects: 1000
Study 32441643 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) administered subcutaneously at 162 mg every 1 or 2 weeks in the GiACTA trial.
Number of subjects: 385
Study 32441643 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) administered via standard IV dose (8 mg/kg/month) or subcutaneously (162 mg/week) in clinical practice.
Number of subjects: 385
Study 32441643 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 385
Study 35956412 — intervention group
Group type: EXPERIMENTAL
Intervention: Study formulation (A)
Number of subjects: 0
Study 35956412 — intervention group
Group type: EXPERIMENTAL
Intervention: Study formulation + eye lubricant (A + L)
Number of subjects: 0
Study 35956412 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 0
Study 35956412 — intervention group
Group type: COMPARATOR
Intervention: Placebo + eye lubricant (P + L)
Number of subjects: 0
Study 34963483 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth coaching via a smartphone application alongside usual care
Number of subjects: 800
Study 34963483 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 800
Study 36131346 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully vaccinated individuals aged 18-64
Number of subjects: 2419
Study 36131346 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated individuals aged 18-64
Number of subjects: 2419
Study 36131346 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated individuals aged 45-64
Number of subjects: 2419
Study 36131346 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated individuals aged 18-25
Number of subjects: 2419
Study 33901754 — intervention group
Group type: EXPERIMENTAL
Intervention: Forest exposure (monoterpenes: alpha‐pinene, beta‐pinene, alpha‐phellandrene, limonene)
Number of subjects: 0
Study 33901754 — intervention group
Group type: COMPARATOR
Intervention: Control group (urban environment)
Number of subjects: 0
Study 33901754 — intervention group
Group type: EXPERIMENTAL
Intervention: Forest exposure
Number of subjects: 0
Study 32175881 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tcVNS stimulation
Number of subjects: 26
Study 32175881 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 26
Study 33523037 — intervention group
Group type: EXPERIMENTAL
Intervention: Equine riding (EQG, n=15)
Number of subjects: 30
Study 33523037 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON, n=15)
Number of subjects: 30
Study 34151544 — intervention group
Group type: EXPERIMENTAL
Intervention: Conical connection systems
Number of subjects: 56
Study 34151544 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight connection systems
Number of subjects: 56
Study 34151544 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 56
Study 32690008 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-guided interactive Visual Telehealth Consultation (VTC) for clinical decision-making, plus telephone follow-up.
Number of subjects: 16
Study 32690008 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE service in ED responding to RACFs with protocol-guided VTC.
Number of subjects: 16
Study 33098739 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC intervention (N=32)
Number of subjects: 76
Study 33098739 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk group
Number of subjects: 76
Study 33098739 — intervention group
Group type: COMPARATOR
Intervention: DEF intervention (N=44)
Number of subjects: 76
Study 32284323 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of diabetes in kidney transplant patients
Number of subjects: 0
Study 32284323 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of secondary hyperparathyroidism in kidney transplant patients
Number of subjects: 0
Study 32284323 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of obesity in kidney transplant patients
Number of subjects: 0
Study 35728892 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline implementation tool arm
Number of subjects: 535
Study 35728892 — intervention group
Group type: COMPARATOR
Intervention: Usual care control arm
Number of subjects: 535
Study 35866833 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus gemcitabine (first-line chemotherapy)
Number of subjects: 56
Study 35866833 — intervention group
Group type: COMPARATOR
Intervention: HT group
Number of subjects: 56
Study 33639007 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal nontouch biofield therapy
Number of subjects: 64
Study 33639007 — intervention group
Group type: COMPARATOR
Intervention: Sham session
Number of subjects: 64
Study 35565731 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol 75 mg twice daily for three months
Number of subjects: 62
Study 35565731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 33227913 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-gravity treadmill training
Number of subjects: 34
Study 33227913 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional therapy)
Number of subjects: 34
Study 32569126 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of caffeine per kg body mass
Number of subjects: 100
Study 32569126 — intervention group
Group type: COMPARATOR
Intervention: 0 mg of caffeine per kg body mass (placebo)
Number of subjects: 100
Study 32569126 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of caffeine per kg body mass
Number of subjects: 100
Study 33379851 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Negative Pressure Therapy (SNPT)
Number of subjects: 53
Study 33379851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic Alternating Negative Pressure Therapy (CANPT)
Number of subjects: 53
Study 33379851 — intervention group
Group type: COMPARATOR
Intervention: Routine Dressing Change (RDC)
Number of subjects: 53
Study 35787128 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure of a PD diagnosis (Borderline, Antisocial, Mild, Moderate, Severe)
Number of subjects: 328
Study 35787128 — intervention group
Group type: COMPARATOR
Intervention: Withholding a PD diagnosis
Number of subjects: 328
Study 35787128 — intervention group
Group type: EXPERIMENTAL
Intervention: Different diagnostic classifications (Borderline, Antisocial, Mild, Moderate, Severe)
Number of subjects: 328
Study 33138628 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus 100 mg aspirin daily
Number of subjects: 3313
Study 33138628 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 3313
Study 35585282 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg for 24 weeks
Number of subjects: 50
Study 35585282 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 50
Study 34274023 — intervention group
Group type: EXPERIMENTAL
Intervention: Bag-valve mask (BVM) ventilation with positive end-expiratory pressure (PEEP)
Number of subjects: 0
Study 34274023 — intervention group
Group type: COMPARATOR
Intervention: Conventional bag-valve mask (BVM) ventilation
Number of subjects: 0
Study 35596117 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-1014-6470 (0.5-200 mg)
Number of subjects: 6
Study 35596117 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-1014-6470 (10 mg) under fasted conditions
Number of subjects: 6
Study 35596117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 35596117 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-1014-6470
Number of subjects: 6
Study 33151286 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoximod plus taxane (paclitaxel 80 mg/m2 weekly or docetaxel 75 mg/m2 every 3 weeks)
Number of subjects: 164